Cryomass Technologies OTC Stock Executives
| CRYM Stock | USD 0.02 0.0001 0.62% |
Cryomass Technologies employs about 7 people. The company is managed by 7 executives with a total tenure of roughly 17 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Cryomass Technologies' management performance can provide insight into the firm performance.
| BA BA Insider Chief Officer |
| Caroline Lenardon Insider Consultant |
Cryomass |
Cryomass Technologies Management Team Effectiveness
The company has return on total asset (ROA) of (0.3296) % which means that it has lost $0.3296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1644) %, meaning that it created substantial loss on money invested by shareholders. Cryomass Technologies' management efficiency ratios could be used to measure how well Cryomass Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Cryomass Technologies Workforce Comparison
Cryomass Technologies is rated fourth in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 579. Cryomass Technologies claims roughly 7.0 in number of employees contributing just under 2% to equities under Drug Manufacturers—Specialty & Generic industry.
Cryomass Technologies Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Cryomass Technologies Price Series Summation is a cross summation of Cryomass Technologies price series and its benchmark/peer.
Cryomass Technologies Notable Stakeholders
A Cryomass Technologies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cryomass Technologies often face trade-offs trying to please all of them. Cryomass Technologies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cryomass Technologies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| BA BA | Chief Officer | Profile | |
| Caroline Lenardon | Consultant | Profile | |
| Ryan Smith | Chief Meds | Profile | |
| Christian Noel | CEO Director | Profile | |
| Janice Matthews | Consultant | Profile | |
| Patricia Kovacevic | Corp Counsel | Profile | |
| Stephen Schroeder | Consultant | Profile |
About Cryomass Technologies Management Performance
The success or failure of an entity such as Cryomass Technologies often depends on how effective the management is. Cryomass Technologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cryomass management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cryomass management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cryomass Technologies Inc. designs, sells, and commercializes cryo-mechanical system for the handling of harvested hemp, cannabis, and other high-value plants. Cryomass Technologies Inc. was incorporated in 2011 and is headquartered in Denver, Colorado. Cryomass Technologies operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
The data published in Cryomass Technologies' official financial statements typically reflect Cryomass Technologies' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Cryomass Technologies' quantitative information. For example, before you start analyzing numbers published by Cryomass accountants, it's essential to understand Cryomass Technologies' liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Cryomass Technologies Workforce Analysis
Traditionally, organizations such as Cryomass Technologies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cryomass Technologies within its industry.Cryomass Technologies Manpower Efficiency
Return on Cryomass Technologies Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.8M | |
| Net Loss Per Executive | 1.8M |
Other Information on Investing in Cryomass OTC Stock
Cryomass Technologies financial ratios help investors to determine whether Cryomass OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cryomass with respect to the benefits of owning Cryomass Technologies security.